江苏鱼跃医疗设备股份有限公司2025年半年度报告摘要

Core Points - The company has approved a cash dividend distribution plan for the first half of 2025, proposing a cash dividend of 2.00 RMB per 10 shares, totaling approximately 200.50 million RMB based on the current total share capital [2][27][29] - The company has received medical device registration certificates for its continuous glucose monitoring systems, enhancing its product offerings in diabetes care [4][6] - The company has invested approximately 27.21 million USD in Inogen, acquiring 9.9% of its shares and establishing a strategic cooperation agreement [7] - The company has obtained EU MDR certification for its automated external defibrillator (AED) products, which will enhance its competitiveness in the emergency medical equipment market [9][10] - The company has extended the duration of its employee stock ownership plan by 24 months, now set to expire in August 2027 [30][31] Financial Data - The company's net profit for the first half of 2025 was approximately 876.29 million RMB, with a distributable profit of about 8.51 billion RMB as of June 30, 2025 [27][29] - The total number of shares for the cash dividend distribution is based on the company's existing total share capital of 1,002,476,929 shares [27][29] Corporate Governance - The company held its sixth board meeting on August 22, 2025, where the half-year report and profit distribution plan were approved [14][26] - The supervisory board also approved the half-year report and profit distribution plan, confirming compliance with legal and regulatory requirements [21][23]